Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients
with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating
alterations (mutations) in cell cycle genes that have spread to other places in the body and
have come back or do not respond to treatment. Palbociclib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.
I. To determine the objective response rate (ORR; complete response + partial response) in
pediatric patients treated with palbociclib with advanced solid tumors (including central
nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor
activating genetic alterations in cell cycle genes.
I. To estimate the progression free survival in pediatric patients treated with palbociclib
with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic
disorders that harbor activating genetic alterations in alterations in cell cycle genes.
II. To obtain information about the tolerability of palbociclib in children and adolescents
with relapsed or refractory cancer.
I. To explore approaches to profiling changes in tumor genomics over time through evaluation
of circulating tumor deoxyribonucleic acid (DNA).
Patients receive palbociclib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 28
days for up to 2 years in the absence of disease progression or unacceptable toxicity.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.